Supply Chain entity
Of the tracked stories, 1 of 2 also mention 340B Drug Pricing Program, the most common co-covered peer. That works out to roughly 1 story per week across a 14-day span. They are better corroborated than the beat average, carrying 2.5 original sources each against 2.4 for the same window.
Last mentioned: Aug 7, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention 340B Drug Pricing Program, the most common co-covered peer. That works out to roughly 1 story per week across a 14-day span. They are better corroborated than the beat average, carrying 2.5 original sources each against 2.4 for the same window. The clearest coverage concentration is disruptions: 1 of 2 stories, with the rest divided among 1 other category. At 6.5, the average consequence score sits above the same-window beat average of 6. This profile follows 2 Supply Chain stories mentioning generic drugs across the period from July 25, 2026 to August 7, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 150 Supply Chain stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering generic drugs. Shared-story counts are live from our verified record — not editorial picks.
Tariff Escalates to 200%
The tariff rate doubles to 200% on generic drug imports.
100% Tariff Takes Effect
A 100% duty is imposed on eligible generic drug imports.
Duty‑Free Period Begins
Imported generics enter a two‑year duty‑free window.
Generic Drug Tariff Schedule Announced
The President announces that generic drugs will remain duty‑free for two years, then face 100% (2028) and 200% (2029) tariffs under Section 232.
Executive Order Tariffs Patented Medicines
President Trump signs an order imposing 100% tariffs on imported patented drugs while exempting generics, biosimilars, and their ingredients.
The impending 100% tariff on imported generic drugs could trigger widespread product discontinuations, as thin margins and pricing constraints block pass-through costs. With three to five years needed to build FDA-approved plants, supply chain disruptions are inevitable. The analysis explores manufacturing dependencies and risk exposure.
Logistics and procurement teams face immediate disruption as a 50% levy on Canadian goods and a sweeping forced-labor tariff covering 60 nations threaten to rewire cross-border supply chains, with the generic drug tariff adding long-term pharma upheaval.
Source: channelnewsasia.com · manilatimes.net
generic drugs is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
